503 filings
Page 16 of 26
6-K
mujx1th
22 Mar 22
Current report (foreign)
4:10pm
6-K
nnl3 9ysh94nsc2f3z0u
17 Mar 22
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
9:48am
6-K
8iah 4ey9
16 Mar 22
Current report (foreign)
5:13pm
6-K
5xytkv
16 Mar 22
2021 Annual Report A nn ua l R ep or t 20 21
4:55pm
6-K
qf8prur0uefbjokzj1
15 Mar 22
Current report (foreign)
4:12pm
6-K
icdxbp
11 Mar 22
Conference Call Alert
6:04am
6-K
hmttyxbuilxpsihc
10 Mar 22
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014
11:21am
6-K
4586q 18ku18kqwh
25 Jan 22
MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards’ Gender Equality Index Report
7:16am
6-K
axq pjngkotq
11 Jan 22
Current report (foreign)
10:08am
6-K
63ypv6l jr
10 Jan 22
MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
12:34pm
6-K
9ako eej94
7 Jan 22
MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
6:39am
6-K
utgp1qkww94nv1nx3rb
13 Dec 21
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
10:14am
6-K
0b6wspc16
13 Dec 21
Current report (foreign)
9:56am
6-K
ixmzwjup55vcq486ahb
7 Dec 21
Current report (foreign)
6:01am
6-K
028jll
29 Nov 21
Current report (foreign)
4:09pm
6-K
x58ofg
26 Nov 21
Current report (foreign)
8:15am
6-K
gxqtqxscry133
23 Nov 21
Current report (foreign)
10:32am
6-K
470jkmy bws2wi
12 Nov 21
MorphoSys AG Reports First Nine Months and Third Quarter
8:30am
6-K
39ew7cd
10 Nov 21
Third Quarter Interim Statement JANUARY – SEPTEMBER
4:05pm
6-K
46vj6wiuin415t
10 Nov 21
MorphoSys Announces Departure of Roland Wandeler
6:14am